Sequential use of targeted agents in the treatment of renal cell carcinoma
Authors:
- Thomas E. HutsonTHThomas E. Hutson
- Ronald M. BukowskiRBRonald M. Bukowski
- C. Lance CoweyCCC. Lance Cowey
- Robert FiglinRFRobert Figlin
- Bernard EscudierBEBernard Escudier
- Cora N. SternbergCSCora N. Sternberg
- 1 January 2011
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 77 (1) , 48-62
Abstract
No abstract availableKeywords
This publication has 77 references indexed in Scilit:
- Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGETMedical Oncology, 2009
- Sequential Sorafenib and Sunitinib for Renal Cell CarcinomaJournal of Urology, 2009
- Innovations and challenges in renal cancer: Summary statement from the Third Cambridge ConferenceCancer, 2009
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- Cardiotoxicity associated with tyrosine kinase inhibitor sunitinibThe Lancet, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancerNature Medicine, 2005
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000